Compare VANI & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VANI | ANIX |
|---|---|---|
| Founded | 1998 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.8M | 104.0M |
| IPO Year | 2014 | 2013 |
| Metric | VANI | ANIX |
|---|---|---|
| Price | $1.50 | $2.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.50 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 266.9K | 106.8K |
| Earning Date | 05-12-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,000,000.00 | $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $2.44 |
| 52 Week High | $1.92 | $5.46 |
| Indicator | VANI | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 69.25 | 55.38 |
| Support Level | $1.19 | $2.74 |
| Resistance Level | $1.55 | $3.10 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 85.04 | 80.00 |
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.